[{"model": "coag.coag", "pk": 1, "fields": {"drugName": "Abciximab", "nx_hold_b_p": "Avoid until normal platelet function has recovered.", "nx_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "nx_hold_b_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "nx_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_p": "Avoid until normal platelet function has recovered.", "db_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "Avoid until normal platelet function has recovered.", "ap_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitate assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued antithrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal."}}, {"model": "coag.coag", "pk": 2, "fields": {"drugName": "Apixaban", "nx_hold_b_p": "72hrs.\r\nWe suggest that the drug to be discontinued 72hrs prior to neuraxial block. Consider checking the drug or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual apixaban activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "nx_hold_b_c": "26-30hrs or anti-factor Xa assay", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "72hrs.\r\nWe suggest that the drug to be discontinued 72hrs prior to neuraxial block. Consider checking the drug or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual apixaban activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_c": "26-30hrs or anti-factor Xa assay.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "72hrs.\r\nWe suggest that the drug to be discontinued 72hrs prior to neuraxial block. Consider checking the drug or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual apixaban activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "ap_hold_b_c": "26-30hrs or anti-factor Xa assay.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 3, "fields": {"drugName": "Argatroban", "nx_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended."}}, {"model": "coag.coag", "pk": 4, "fields": {"drugName": "Aspirin", "nx_hold_b_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "nx_restart_a_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "nx_hold_b_c": "No restrictions.", "nx_restart_a_c": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "db_hold_b_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "db_restart_a_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "db_hold_b_c": "No restrictions.", "db_restart_a_c": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "ap_restart_a_p": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications.", "ap_hold_b_c": "No restrictions.", "ap_restart_a_c": "No restrictions.\r\nIn patients receiving NSAIDs, we suggest caution in the performance of neuraxial techniques if the concurrent use of other medications affecting clotting mechanisms, such as other anti-platelet agents, oral anti-coagulants, UFH, and LMWH, is anticipated in the early postoperative period because of the increased risk of bleeding complications."}}, {"model": "coag.coag", "pk": 5, "fields": {"drugName": "Betrixaban", "nx_hold_b_p": "3days.\r\nWe suggest that the drug be discontinued a minimum of 3 days prior to neuraxial block. Consider checking the drug level or anti-factor Xa level if less than 3 days.", "nx_restart_a_p": "At least 5hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 5hrs prior to the first dose.", "nx_hold_b_c": "72hrs.", "nx_restart_a_c": "5hrs.\r\nWe suggest that neuraxial catheters 5hrs be removed prior to next dose.", "db_hold_b_p": "3days.\r\nWe suggest that the drug be discontinued a minimum of 3 days prior to neuraxial block. Consider checking the drug level or anti-factor Xa level if less than 3 days.", "db_restart_a_p": "At least 5hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 5hrs prior to the first dose.", "db_hold_b_c": "72hrs.", "db_restart_a_c": "5hrs.\r\nWe suggest that neuraxial catheters 5hrs be removed prior to next dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "3days.\r\nWe suggest that the drug be discontinued a minimum of 3 days prior to neuraxial block. Consider checking the drug level or anti-factor Xa level if less than 3 days.", "ap_restart_a_p": "At least 5hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 5hrs prior to the first dose.", "ap_hold_b_c": "72hrs.", "ap_restart_a_c": "5hrs.\r\nWe suggest that neuraxial catheters 5hrs be removed prior to next dose."}}, {"model": "coag.coag", "pk": 6, "fields": {"drugName": "Bivalirudin", "nx_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended."}}, {"model": "coag.coag", "pk": 7, "fields": {"drugName": "Cangrelor", "nx_hold_b_p": "Minimum 3hrs.", "nx_restart_a_p": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_p": "Minimum 3hrs.", "db_restart_a_p": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "Minimum 3hrs.", "ap_restart_a_p": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "8rhs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal."}}, {"model": "coag.coag", "pk": 8, "fields": {"drugName": "Cilostazol", "nx_hold_b_p": "2days.\r\nBased on the elimination of half-life, we suggest that neuraxial techniques be avoided for 2days after discontinuation of this drug.", "nx_restart_a_p": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_p": "2days.\r\nBased on the elimination of half-life, we suggest that neuraxial techniques be avoided for 2days after discontinuation of this drug.", "db_restart_a_p": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "2days.\r\nBased on the elimination of half-life, we suggest that neuraxial techniques be avoided for 2days after discontinuation of this drug.", "ap_restart_a_p": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal."}}, {"model": "coag.coag", "pk": 9, "fields": {"drugName": "Clopidogrel", "nx_hold_b_p": "5-7days.", "nx_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "nx_hold_b_c": "No information.", "nx_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.", "db_hold_b_p": "5-7days.", "db_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "db_hold_b_c": "No information.", "db_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.", "sp_hold_b_p": "No information.", "sp_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "sp_hold_b_c": "No information.", "sp_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.", "ap_hold_b_p": "5-7days.", "ap_restart_a_p": "Immediately, if no loading dose & 24hrs postop.\r\nIn accordance with ACCP recommendations, thienopyridine therapy may be re-instituted 24hrs postoperatively.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration.\r\nBecause the antiplatelet effect is not immediate with ticlopidine and clopidogrel, neuraxial catheters may be maintained for 1~2days, provided a loading dose of the anti-platelet agent is not administered.", "ap_hold_b_c": "No information.", "ap_restart_a_c": "Immediately, if no loading dose.\r\nIf a loading dose is administered, we suggest a time interval of 6hrs between needle placement and administration."}}, {"model": "coag.coag", "pk": 10, "fields": {"drugName": "Dabigatran", "nx_hold_b_p": "120hrs.\r\nWe suggest that dabigatran be discontinued 120hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding, a more graded approach may be considered.\r\nWe suggest that dabigatran be discontinued 72hrs in patients with a CrCl 80ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 72hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 96hrs in patients with a CrCl 50~79ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 96hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 120hrs in patients with a CrCl 30~49ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 120hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest against the performance of neuraxial blocks in CrCl<30ml/min.", "nx_restart_a_p": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "nx_hold_b_c": "34-36hrs or dTT/ECT testing.", "nx_restart_a_c": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "120hrs.\r\nWe suggest that dabigatran be discontinued 120hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding, a more graded approach may be considered.\r\nWe suggest that dabigatran be discontinued 72hrs in patients with a CrCl 80ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 72hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 96hrs in patients with a CrCl 50~79ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 96hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 120hrs in patients with a CrCl 30~49ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 120hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest against the performance of neuraxial blocks in CrCl<30ml/min.", "db_restart_a_p": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_c": "34-36hrs or dTT/ECT testing.", "db_restart_a_c": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "120hrs.\r\nWe suggest that dabigatran be discontinued 120hrs prior to neuraxial block. However, if renal function has been reliably determined, and there are no additional risk factors for bleeding, a more graded approach may be considered.\r\nWe suggest that dabigatran be discontinued 72hrs in patients with a CrCl 80ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 72hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 96hrs in patients with a CrCl 50~79ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 96hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest that dabigatran be discontinued 120hrs in patients with a CrCl 30~49ml/min or greater. Consider checking dTT or ecarin clotting time(ECT) if less than 120hrs. An acceptable level of residual dabigatran activity to proceed with neuraxial block remains undetermined.\r\nWe suggest against the performance of neuraxial blocks in CrCl<30ml/min.", "ap_restart_a_p": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "ap_hold_b_c": "34-36hrs or dTT/ECT testing.", "ap_restart_a_c": "6hrs.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 11, "fields": {"drugName": "Dalteparin(prophylaxis)", "nx_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs preoperatively, we recommend against neuraxial techniques because needle placement would occur close to peak anti-coagulant activity.", "nx_restart_a_p": "First dose 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "nx_hold_b_c": "12hrs.", "nx_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "db_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs preoperatively, we recommend against neuraxial techniques because needle placement would occur close to peak anti-coagulant activity.", "db_restart_a_p": "First dose 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "db_hold_b_c": "12hrs.", "db_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs preoperatively, we recommend against neuraxial techniques because needle placement would occur close to peak anti-coagulant activity.", "ap_restart_a_p": "First dose 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "ap_hold_b_c": "12hrs.", "ap_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement."}}, {"model": "coag.coag", "pk": 12, "fields": {"drugName": "Dalteparin(therapeutic)", "nx_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment dose of 200U/kg or 100U/kg q12hrs.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "24-72hrs.\r\nTherapeutic-dose LMWH may be resumed 24hrs after non-high-bleeding risk surgery and 48~72hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "nx_hold_b_c": "Avoid.", "nx_restart_a_c": "At least 4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement whichever is greater.", "db_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment dose of 200U/kg or 100U/kg q12hrs.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "24-72hrs.\r\nTherapeutic-dose LMWH may be resumed 24hrs after non-high-bleeding risk surgery and 48~72hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "db_hold_b_c": "Avoid.", "db_restart_a_c": "At least 4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement whichever is greater.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment dose of 200U/kg or 100U/kg q12hrs.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "24-72hrs.\r\nTherapeutic-dose LMWH may be resumed 24hrs after non-high-bleeding risk surgery and 48~72hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "ap_hold_b_c": "Avoid.", "ap_restart_a_c": "At least 4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement whichever is greater."}}, {"model": "coag.coag", "pk": 13, "fields": {"drugName": "Desirudin", "nx_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_restart_a_p": "AVOID.\r\nNeuraxial technique not recommended.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nNeuraxial technique not recommended."}}, {"model": "coag.coag", "pk": 14, "fields": {"drugName": "Dipyridamole", "nx_hold_b_p": "24hrs.\r\nBased on the elimination half-life, we suggest discontinuing extended-release dipyridamole for 24hrs prior to neuraxial block. Aspirin may be continued perioperatively.", "nx_restart_a_p": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_p": "24hrs.\r\nBased on the elimination half-life, we suggest discontinuing extended-release dipyridamole for 24hrs prior to neuraxial block. Aspirin may be continued perioperatively.", "db_restart_a_p": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "24hrs.\r\nBased on the elimination half-life, we suggest discontinuing extended-release dipyridamole for 24hrs prior to neuraxial block. Aspirin may be continued perioperatively.", "ap_restart_a_p": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "6hrs, AVOID with indwelling catheters.\r\nWe suggest that neuraxial catheters be removed prior to reinstitution of this drug therapy postoperatively.\r\nWe suggest that the first postoperative period dose of this drug be administered 8hrs after neuraxial catheter removal."}}, {"model": "coag.coag", "pk": 15, "fields": {"drugName": "Edoxaban", "nx_hold_b_p": "72hrs.\r\nWe suggest that edoxaban be discontinued 72hrs prior to neuraxial block. Consider checking edoxaban or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual edoxaban activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "nx_hold_b_c": "20-28hrs or anti-factor Xa assay", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "72hrs.\r\nWe suggest that edoxaban be discontinued 72hrs prior to neuraxial block. Consider checking edoxaban or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual edoxaban activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_c": "20-28hrs or anti-factor Xa assay.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "72hrs.\r\nWe suggest that edoxaban be discontinued 72hrs prior to neuraxial block. Consider checking edoxaban or anti-factor Xa activity level if less than 72hrs. An acceptable level of residual edoxaban activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "At least 6hrs, AVOID with indwelling catheters.\r\nIndwelling catheters should be removed prior to initiation of the drug.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "ap_hold_b_c": "20-28hrs or anti-factor Xa assay.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 16, "fields": {"drugName": "Enoxaparin(prophylaxisBID)", "nx_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "nx_restart_a_p": "First dose the following day, Minimum 12hrs after needle/catheter.\r\nIndwelling catheters should be removed prior to initiation of LMWH.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "At least 4hrs.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "db_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "db_restart_a_p": "First dose the following day, Minimum 12hrs after needle/catheter.\r\nIndwelling catheters should be removed prior to initiation of LMWH.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "At least 4hrs.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "ap_restart_a_p": "First dose the following day, Minimum 12hrs after needle/catheter.\r\nIndwelling catheters should be removed prior to initiation of LMWH.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "At least 4hrs.\r\nThis dosage regimen is associated with an increased risk of spinal hematoma.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered the following day and no earlier than 12hrs after needle/catheter placement, regardless of anesthetic technique, and only in the presence of adequate hemostasis."}}, {"model": "coag.coag", "pk": 17, "fields": {"drugName": "Enoxaparin(prophylaxisQD)", "nx_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "nx_restart_a_p": "First dose at least 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "nx_hold_b_c": "12hrs.", "nx_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "db_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "db_restart_a_p": "First dose at least 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "db_hold_b_c": "12hrs.", "db_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs.\r\nWe recommend that needle placement should occur at least 12hrs after a prophylactic LMWH dose.\r\nIn patients administered a dose of LMWH 2hrs pre-operatively, we recommend against neuraxial techniques because needle placement would occur close to peak anticoagulant activity.", "ap_restart_a_p": "First dose at least 12hrs.\r\nWe recommend the first postoperative LMWH dose should be administered at least 12hrs after needle/catheter placement. The second postoperative dose should occur no sooner than 24hrs after the first dose.\r\nIndwelling neuraxial catheters do not represent increased risk and may be maintained. However, no additional risk and may be maintained. However, no additional hemostasis altering medications should be administered because of the additive effects.", "ap_hold_b_c": "12hrs.", "ap_restart_a_c": "At least 4hrs.\r\nAdministration of LMWH should be delayed for 4hrs after catheter removal. We recommend the first dose of LMWH should be administered no earlier than 12hrs after needle/catheter placement."}}, {"model": "coag.coag", "pk": 18, "fields": {"drugName": "Enoxaparin(therapeutic)", "nx_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment doses of 1mg/kg/ q12hrs or 1.5mg/kg daily.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "nx_restart_a_p": "24-72hrs.\r\nTherapeutic dose LMWH may be resumed 24hrs after non-high-bleeding-risk surgery and 48 to 72 hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement, whichever is greater.", "db_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment doses of 1mg/kg/ q12hrs or 1.5mg/kg daily.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "db_restart_a_p": "24-72hrs.\r\nTherapeutic dose LMWH may be resumed 24hrs after non-high-bleeding-risk surgery and 48 to 72 hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement, whichever is greater.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "24hrs.\r\nDelay needle insertion at least 24hrs for treatment doses of 1mg/kg/ q12hrs or 1.5mg/kg daily.\r\nConsider checking anti-factor Xa level, particularly in elderly patients and patients with renal insufficiency. An acceptable level of residual anti-factor Xa activity to proceed with neuraxial block remains undetermined.", "ap_restart_a_p": "24-72hrs.\r\nTherapeutic dose LMWH may be resumed 24hrs after non-high-bleeding-risk surgery and 48 to 72 hrs after high-bleeding-risk surgery.\r\nIndwelling catheters should be removed before initiation none of therapeutic LMWH treatment.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "4hrs.\r\nWe recommend that indwelling neuraxial catheters be removed 4hrs prior to the first postoperative dose and at least 24hrs after needle/catheter placement, whichever is greater."}}, {"model": "coag.coag", "pk": 19, "fields": {"drugName": "Eptifibatide", "nx_hold_b_p": "AVOID until normal platelet function has recovered.\r\nWe recommend that neuraxial techniques should be avoided until platelet function as impacted by the GP IIb/IIIa inhibitor has recovered.\r\nFollowing administration, the time to normal platelet aggregation is 4 to 8 hours for eptifibatide.", "nx_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_p": "AVOID until normal platelet function has recovered.\r\nWe recommend that neuraxial techniques should be avoided until platelet function as impacted by the GP IIb/IIIa inhibitor has recovered.\r\nFollowing administration, the time to normal platelet aggregation is 4 to 8 hours for eptifibatide.", "db_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "AVOID until normal platelet function has recovered.\r\nWe recommend that neuraxial techniques should be avoided until platelet function as impacted by the GP IIb/IIIa inhibitor has recovered.\r\nFollowing administration, the time to normal platelet aggregation is 4 to 8 hours for eptifibatide.", "ap_restart_a_p": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "AVOID.\r\nAlthough GP IIb/IIIa antagonists are contraindicated within 4weeks of surgery, should one be emergently administered in the postoperative period, we recommend the infusion should be limited to drugs minimizing sensory and motor block to facilitated assessment of neurologic function and that the patient be carefully monitored neurologically. Timing of catheter removal is based on ongoing risk of thromboembolism and need for continued anti-thrombotic therapy and the potential for spinal bleeding during catheter maintenance and removal."}}, {"model": "coag.coag", "pk": 20, "fields": {"drugName": "Fondaparinux", "nx_hold_b_p": "NO RECOMMENDATION.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "nx_restart_a_p": "AVOID.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "nx_hold_b_c": "AVOID.", "nx_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "db_hold_b_p": "NO RECOMMENDATION.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "db_restart_a_p": "AVOID.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "db_hold_b_c": "AVOID.", "db_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "NO RECOMMENDATION.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "ap_restart_a_p": "AVOID.\r\nBased on the sustained and irreversible antithrombotic  effect, early postoperative dosing, and the spinal hematoma reported during initial clinical trials, we recommend that until further clinical experience is available performance of neuraxial techniques should occur under conditions used in clinical trials. If this is not feasible, an alternate method of prophylaxis should be considered.", "ap_hold_b_c": "AVOID.", "ap_restart_a_c": "6hrs.\r\nWe suggest that neuraxial catheters be removed 6hrs prior to the first dose."}}, {"model": "coag.coag", "pk": 21, "fields": {"drugName": "Heparin(CPB)", "nx_hold_b_p": "Neuraxial blocks should be avoided in a patient with known coagulopathy from any cause.", "nx_restart_a_p": "60min.\r\nTime from instrumentation to systemic heparinization should exceed 60mins. Surgery should be delayed 24hrs in the event of a traumatic tap.", "nx_hold_b_c": "After normal coagulation restored.", "nx_restart_a_c": "No recommendation.", "db_hold_b_p": "Neuraxial blocks should be avoided in a patient with known coagulopathy from any cause.", "db_restart_a_p": "60min.\r\nTime from instrumentation to systemic heparinization should exceed 60mins. Surgery should be delayed 24hrs in the event of a traumatic tap.", "db_hold_b_c": "After normal coagulation restored.", "db_restart_a_c": "No recommendation", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "Neuraxial blocks should be avoided in a patient with known coagulopathy from any cause.", "ap_restart_a_p": "60min.\r\nTime from instrumentation to systemic heparinization should exceed 60mins. Surgery should be delayed 24hrs in the event of a traumatic tap.", "ap_hold_b_c": "After normal coagulation restored.", "ap_restart_a_c": "No recommendation."}}, {"model": "coag.coag", "pk": 22, "fields": {"drugName": "Heparin(IV)", "nx_hold_b_p": "4~6hrs & Normal coagulation status.\r\nDiscontinue heparin infusion 4~6hrs and verify normal coagulation status prior to neuraxial blockade. Avoid neuraxial techniques in patients with other coagulopathies.", "nx_restart_a_p": "1hr.\r\nAlthough the occurrence of a bloody or difficult neuraxial needle placement may increase risk, there are no data to support mandatory cancellation of a case. Direct communication with the surgeon and a specific risk-benefit decision about proceeding in each case are warranted.\r\nCurrently, insufficient data and experience are available to determine if the risk of neuraxial hematoma is increased when combining neuraxial techniques with the full anti-coagulation of cardiac surgery. We suggest postoperative monitoring of neurologic function and selection of neuraxial solutions that minimize sensory and motor block to facilitate detection of new/progressive neurodeficits.", "nx_hold_b_c": "4~6hrs & Normal coagulation status.", "nx_restart_a_c": "1hr.\r\nReheparinize 1hr after catheter removal.", "db_hold_b_p": "4~6hrs & Normal coagulation status.\r\nDiscontinue heparin infusion 4~6hrs and verify normal coagulation status prior to neuraxial blockade. Avoid neuraxial techniques in patients with other coagulopathies.", "db_restart_a_p": "1hr.\r\nAlthough the occurrence of a bloody or difficult neuraxial needle placement may increase risk, there are no data to support mandatory cancellation of a case. Direct communication with the surgeon and a specific risk-benefit decision about proceeding in each case are warranted.\r\nCurrently, insufficient data and experience are available to determine if the risk of neuraxial hematoma is increased when combining neuraxial techniques with the full anti-coagulation of cardiac surgery. We suggest postoperative monitoring of neurologic function and selection of neuraxial solutions that minimize sensory and motor block to facilitate detection of new/progressive neurodeficits.", "db_hold_b_c": "4~6hrs & Normal coagulation status.", "db_restart_a_c": "1hr.\r\nReheparinize 1hr after catheter removal.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "4~6hrs & Normal coagulation status.\r\nDiscontinue heparin infusion 4~6hrs and verify normal coagulation status prior to neuraxial blockade. Avoid neuraxial techniques in patients with other coagulopathies.", "ap_restart_a_p": "1hr.\r\nAlthough the occurrence of a bloody or difficult neuraxial needle placement may increase risk, there are no data to support mandatory cancellation of a case. Direct communication with the surgeon and a specific risk-benefit decision about proceeding in each case are warranted.\r\nCurrently, insufficient data and experience are available to determine if the risk of neuraxial hematoma is increased when combining neuraxial techniques with the full anti-coagulation of cardiac surgery. We suggest postoperative monitoring of neurologic function and selection of neuraxial solutions that minimize sensory and motor block to facilitate detection of new/progressive neurodeficits.", "ap_hold_b_c": "4~6hrs & Normal coagulation status.", "ap_restart_a_c": "1hr.\r\nReheparinize 1hr after catheter removal."}}, {"model": "coag.coag", "pk": 23, "fields": {"drugName": "Heparin(SCprophylaxis)", "nx_hold_b_p": "12hrs & assessment of coagulation status.\r\nPreoperative higher-dose UFH for thromboprophylaxis. We suggest neuraxial block occur 12hrs after SC heparin administration and assessment of coagulation status.", "nx_restart_a_p": "Unknown risk. Risk-Benefit assessment required.\r\nThe safety of indwelling neuraxial catheters in patients receiving doses greater than 5000U or greater than 15000U of UFH daily has not been established. We suggest that the risk and benefits be assessed on an individual basis and that techniques to facilitate detection of new/progressive neurodeficits be applied.", "nx_hold_b_c": "Unknown risk. Risk-Benefit assessment required.", "nx_restart_a_c": "Immediately.", "db_hold_b_p": "12hrs & assessment of coagulation status.\r\nPreoperative higher-dose UFH for thromboprophylaxis. We suggest neuraxial block occur 12hrs after SC heparin administration and assessment of coagulation status.", "db_restart_a_p": "Unknown risk. Risk-Benefit assessment required.\r\nThe safety of indwelling neuraxial catheters in patients receiving doses greater than 5000U or greater than 15000U of UFH daily has not been established. We suggest that the risk and benefits be assessed on an individual basis and that techniques to facilitate detection of new/progressive neurodeficits be applied.", "db_hold_b_c": "Unknown risk. Risk-Benefit assessment required.", "db_restart_a_c": "Immediately.", "sp_hold_b_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_p": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_hold_b_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "sp_restart_a_c": "Management based on site compressibility, vascularity, and consequences of bleeding, should it occur.", "ap_hold_b_p": "12hrs & assessment of coagulation status.\r\nPreoperative higher-dose UFH for thromboprophylaxis. We suggest neuraxial block occur 12hrs after SC heparin administration and assessment of coagulation status.", "ap_restart_a_p": "Unknown risk. Risk-Benefit assessment required.\r\nThe safety of indwelling neuraxial catheters in patients receiving doses greater than 5000U or greater than 15000U of UFH daily has not been established. We suggest that the risk and benefits be assessed on an individual basis and that techniques to facilitate detection of new/progressive neurodeficits be applied.", "ap_hold_b_c": "Unknown risk. Risk-Benefit assessment required.", "ap_restart_a_c": "Immediately."}}, {"model": "board.board", "pk": 1, "fields": {"title": "test", "contents": "test", "author": "test", "created_date": "2024-06-25T05:34:00Z", "modified_date": "2024-06-25T05:34:00Z"}}, {"model": "exam.exam", "pk": 1, "fields": {"title": "test", "description": "test", "date_created": "2024-07-02T14:05:01.460Z"}}, {"model": "exam.exam", "pk": 2, "fields": {"title": "2023 ITE", "description": "2023  \r\n  (In Training Exam, ITE) ", "date_created": "2024-07-04T04:52:00.801Z"}}, {"model": "exam.question", "pk": 1, "fields": {"exam": 1, "question_text": "this is test question1", "image": "question_images/20230929_155209.jpg", "option1": "a1", "option2": "a2", "option3": "a3", "option4": "a4", "option5": "a5", "correct_option": "a5", "comment": "default", "comment_image": ""}}, {"model": "exam.question", "pk": 2, "fields": {"exam": 1, "question_text": "this is test question2", "image": "", "option1": "aa11", "option2": "aa22", "option3": "aa33", "option4": "aa44", "option5": "aa55", "correct_option": "aa11", "comment": "default", "comment_image": ""}}, {"model": "exam.question", "pk": 3, "fields": {"exam": 2, "question_text": "1.        ?", "image": "", "option1": "  2 ml/kg   ", "option2": "   24  crystalloid   3 L   .", "option3": "  24  (fluid balance) 50 ml/kg    .", "option4": "Third-space loss    ", "option5": "      inotrope   ", "correct_option": "5", "comment": " Urine output greater than 0.5 ml/kg/h is unnecessary.\r\n For an average adult patient, crystalloid administration should be limited to less than 3 L in \r\nthe first 24 h.\r\n Total positive fluid balance in the first 24-h perioperative period should not exceed 20 \r\nmL/kg.\r\n No fluid administration for third-space fluid losses during pulmonary resection.\r\n If increased tissue perfusion is needed postoperatively, it is preferable to use invasive \r\nmonitoring and inotropes rather than to cause fluid overload.\r\n: Miller RD: Millers Anesthesia. 9th ed. pp 1676. BOX 53.11", "comment_image": ""}}, {"model": "exam.question", "pk": 4, "fields": {"exam": 2, "question_text": " 2. 68           \r\n .  3   ,   \r\n    , 5   ,   \r\n .           ?", "image": "", "option1": "     FEV1  FVC         .", "option2": "         opioids  NSAIDs    .", "option3": "         .", "option4": "       vasopressin    .", "option5": "        predicted postoperative FEV1%     .", "correct_option": "", "comment": "       ,      \r\n   . \r\n    cisplatin     NSAIDs    \r\n . \r\n     10%      shunt \r\n   . \r\n Vasopressin          \r\n. \r\n     4    .", "comment_image": ""}}, {"model": "exam.question", "pk": 5, "fields": {"exam": 2, "question_text": " 5. 47       .    propofol 2.0 \r\nmg/kg  rocuronium 1.0 mg/kg  ,    (TOF) 0  . \r\n      3    .   \r\n                 ?", "image": "", "option1": " Propofol  rocuronium  ", "option2": " (cricothyrotomy)", "option3": " (supraglottic airway) ", "option4": " Dexamethasone 5 mg ", "option5": "  (tracheostomy) ", "correct_option": "", "comment": ": 2022 ASA difficult airway algorithm \r\n:  4 , , pp376-7, Millers anesthesia, 9th edition, pp 1375", "comment_image": ""}}, {"model": "exam.question", "pk": 6, "fields": {"exam": 2, "question_text": " 6.             ?", "image": "", "option1": "    .", "option2": "      .", "option3": "  .", "option4": "    .", "option5": "   .", "correct_option": "", "comment": "   (venous thromboembolism) .\r\n    (diastolic dysfunction) .\r\n (afterload) .\r\n   (myocardial oxygen consumption) .\r\n: Michael A. Gropper: Millers Anesthesia. 9th ed. Pp 2103-2104", "comment_image": ""}}, {"model": "exam.question", "pk": 7, "fields": {"exam": 2, "question_text": " 7.             ?", "image": "", "option1": " -   .", "option2": "   .", "option3": " -   .", "option4": "  .", "option5": "   .", "correct_option": "", "comment": " - (-adrenergic sensitivity) .\r\n -  (responsiveness to -agonists) .\r\n (cardiac output) .\r\n  (orthostatic hypotension) .\r\n \r\n: Michael A. Gropper: Millers Anesthesia. 9th ed. Pp 2105", "comment_image": ""}}, {"model": "exam.question", "pk": 8, "fields": {"exam": 2, "question_text": " 8. 88       .    \r\n,   .      \r\n  ,  5   .  \r\n    ,       \r\n  .      \r\n ,       .    \r\n    ?", "image": "", "option1": " 88 ", "option2": "  ", "option3": "    ", "option4": " 5    ", "option5": " ", "correct_option": "", "comment": "Major predisposing patient risk factors include (1) age greater than 65 years, (2) cognitive \r\nimpairment, (3) severe illness or comorbidity burden, (4) hearing or vision impairment, and (5) \r\npresence of infection () Once in the recovery room, any deliriogenic medications should be \r\navoided (e.g., anticholinergics, sedative-hypnotics, meperidine), unless\r\n: Miller RD: Millers Anesthesia. 9th ed. pp 2604", "comment_image": ""}}, {"model": "exam.question", "pk": 9, "fields": {"exam": 2, "question_text": " 9.           position \r\n    ?", "image": "", "option1": " Sniff position  .", "option2": "     .", "option3": " Atlanto-occipital extension   .", "option4": " Ramped position  .", "option5": " Succinylcholine  .", "correct_option": "", "comment": "          \r\nin-line stabilization  .\r\nSuccinylcholine:     succinylcholine    \r\n,        succinylcholine  \r\n. ,       succinylcholine  .\r\n: Millers Anesthesia. 9th ed. pp 1892.\r\n:  pp 160-1", "comment_image": ""}}, {"model": "exam.question", "pk": 10, "fields": {"exam": 2, "question_text": " 10. 35          16 \r\nmm        . \r\n       (visual evoked potential, VEP)\r\n .   VEP      ?", "image": "", "option1": " Sevoflurane", "option2": " Desflurane", "option3": " Etomidate", "option4": " Propofol", "option5": " Rocuronium", "correct_option": "", "comment": ": VEP         . VEP \r\n      .\r\n: , 1st edition p118-133", "comment_image": ""}}, {"model": "exam.question", "pk": 11, "fields": {"exam": 2, "question_text": " 11. 46       (pituitary apoplexy)\r\n    .        \r\n?", "image": "", "option1": " Aldosterone", "option2": " Hydrocortisone", "option3": " Growth hormone", "option4": " Sex hormone", "option5": " Antidiuretic hormone", "correct_option": "", "comment": "Glucocorticoid    . Glucocorticoid   \r\n prostacyclin (PGI2)   .  glucocorticoid  \r\n PGI2        \r\n.    glucocorticoid      , \r\n  cortisol    .\r\n: :  pp275", "comment_image": ""}}, {"model": "exam.question", "pk": 12, "fields": {"exam": 2, "question_text": " 12.    57      \r\n(coil embolization)   .    \r\n    130/70 mmHg    .   \r\n   .      , \r\n    180/130 mmHg  .   \r\n  T-wave inversion   bispectral index (BIS)  54 \r\n10  .     ?", "image": "", "option1": "     ", "option2": "     ", "option3": "      ", "option4": "     ", "option5": "     ", "correct_option": "", "comment": "          .\r\n          \r\n.\r\n: .  4     . pp 223-7", "comment_image": ""}}, {"model": "exam.question", "pk": 13, "fields": {"exam": 2, "question_text": " 13. 55          (skull \r\nbase)      .   \r\n       (hyperchloremic metabolic \r\nacidosis)      ?", "image": "", "option1": " Normal saline", "option2": " Half-saline", "option3": " Lactate Ringer solution", "option4": " 5% dextrose solution", "option5": " PlasmaLyte", "correct_option": "", "comment": ":         \r\n      .\r\n: , 1st edition p150", "comment_image": ""}}, {"model": "exam.question", "pk": 14, "fields": {"exam": 2, "question_text": " 14. 49          \r\n .         \r\n 98% .  50%    pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L .    \r\n  .    ?", "image": "question_images/2023_14.jpeg", "option1": " ", "option2": " ", "option3": " ", "option4": "  ", "option5": " ", "correct_option": "", "comment": "Below the pleura, hyperechoic horizontal reverberation artifacts at regular distances are referred \r\nto as A lines (see Fig. 41.27A).\r\nIn normal aerated lung, hyperechoic, horizontal lines arising at regular intervals from the pleural \r\nline can be seen, which are called A-lines. These are reverberation artifacts that arise when the \r\nultrasound beam reflects off of the pleura and, instead of entering the probe, partially reflects off \r\nof the probe face back to the pleura again before getting back to the machine.\r\nA-line     . \r\n Miller's Anesthesia 9  pp 1328-1329", "comment_image": ""}}, {"model": "admin.logentry", "pk": 1, "fields": {"action_time": "2024-06-24T06:43:18.666Z", "user": 1, "content_type": 1, "object_id": "1", "object_repr": "Coag object (1)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 2, "fields": {"action_time": "2024-06-24T08:01:27.439Z", "user": 1, "content_type": 1, "object_id": "1", "object_repr": "Coag object (1)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 3, "fields": {"action_time": "2024-06-24T08:07:07.700Z", "user": 1, "content_type": 1, "object_id": "2", "object_repr": "Coag object (2)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 4, "fields": {"action_time": "2024-06-24T08:09:05.497Z", "user": 1, "content_type": 1, "object_id": "3", "object_repr": "Coag object (3)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 5, "fields": {"action_time": "2024-06-24T08:13:01.201Z", "user": 1, "content_type": 1, "object_id": "4", "object_repr": "Coag object (4)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 6, "fields": {"action_time": "2024-06-24T08:21:10.645Z", "user": 1, "content_type": 1, "object_id": "5", "object_repr": "Coag object (5)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 7, "fields": {"action_time": "2024-06-24T08:23:07.008Z", "user": 1, "content_type": 1, "object_id": "6", "object_repr": "Coag object (6)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 8, "fields": {"action_time": "2024-06-25T05:34:05.305Z", "user": 1, "content_type": 9, "object_id": "1", "object_repr": "Board object (1)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 9, "fields": {"action_time": "2024-06-26T05:51:56.365Z", "user": 1, "content_type": 6, "object_id": "2", "object_repr": "tests", "action_flag": 3, "change_message": ""}}, {"model": "admin.logentry", "pk": 10, "fields": {"action_time": "2024-06-26T09:20:50.830Z", "user": 1, "content_type": 1, "object_id": "7", "object_repr": "Coag object (7)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 11, "fields": {"action_time": "2024-06-28T05:54:22.153Z", "user": 1, "content_type": 1, "object_id": "8", "object_repr": "Coag object (8)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 12, "fields": {"action_time": "2024-06-28T06:00:10.597Z", "user": 1, "content_type": 1, "object_id": "9", "object_repr": "Coag object (9)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 13, "fields": {"action_time": "2024-06-28T06:07:20.544Z", "user": 1, "content_type": 1, "object_id": "10", "object_repr": "Coag object (10)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 14, "fields": {"action_time": "2024-06-28T06:14:43.839Z", "user": 1, "content_type": 1, "object_id": "11", "object_repr": "Coag object (11)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 15, "fields": {"action_time": "2024-06-28T06:20:17.624Z", "user": 1, "content_type": 1, "object_id": "12", "object_repr": "Coag object (12)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 16, "fields": {"action_time": "2024-06-28T06:22:17.454Z", "user": 1, "content_type": 1, "object_id": "13", "object_repr": "Coag object (13)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 17, "fields": {"action_time": "2024-07-02T14:05:01.462Z", "user": 1, "content_type": 10, "object_id": "1", "object_repr": "test", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 18, "fields": {"action_time": "2024-07-02T14:15:21.841Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "testing", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 19, "fields": {"action_time": "2024-07-02T14:15:41.827Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Question text\"]}}]"}}, {"model": "admin.logentry", "pk": 20, "fields": {"action_time": "2024-07-02T15:14:23.161Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Option1\", \"Option2\", \"Option3\", \"Option4\", \"Correct option\"]}}]"}}, {"model": "admin.logentry", "pk": 21, "fields": {"action_time": "2024-07-02T15:18:57.232Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 22, "fields": {"action_time": "2024-07-02T15:29:53.401Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "q1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Option5\"]}}]"}}, {"model": "admin.logentry", "pk": 23, "fields": {"action_time": "2024-07-02T15:30:02.518Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "this is test question1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Question text\"]}}]"}}, {"model": "admin.logentry", "pk": 24, "fields": {"action_time": "2024-07-02T15:30:22.050Z", "user": 1, "content_type": 11, "object_id": "2", "object_repr": "this is test question2", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 25, "fields": {"action_time": "2024-07-02T15:30:29.578Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "this is test question1", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 26, "fields": {"action_time": "2024-07-02T16:02:51.393Z", "user": 1, "content_type": 11, "object_id": "1", "object_repr": "this is test question1", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Image\"]}}]"}}, {"model": "admin.logentry", "pk": 27, "fields": {"action_time": "2024-07-03T03:56:42.426Z", "user": 1, "content_type": 1, "object_id": "14", "object_repr": "Coag object (14)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 28, "fields": {"action_time": "2024-07-04T04:52:00.807Z", "user": 1, "content_type": 10, "object_id": "2", "object_repr": "2023 ITE", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 29, "fields": {"action_time": "2024-07-04T04:53:43.312Z", "user": 1, "content_type": 11, "object_id": "3", "object_repr": "       ?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 30, "fields": {"action_time": "2024-07-04T04:54:27.955Z", "user": 1, "content_type": 11, "object_id": "3", "object_repr": "1.        ?", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Question text\"]}}]"}}, {"model": "admin.logentry", "pk": 31, "fields": {"action_time": "2024-07-04T05:22:23.153Z", "user": 1, "content_type": 11, "object_id": "3", "object_repr": "1.        ?", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Comment\"]}}]"}}, {"model": "admin.logentry", "pk": 32, "fields": {"action_time": "2024-07-04T05:25:45.712Z", "user": 1, "content_type": 11, "object_id": "4", "object_repr": " 2. 68           \r\n .  3   ,   \r\n    , 5   ,   \r\n .          ", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 33, "fields": {"action_time": "2024-07-04T05:44:23.350Z", "user": 1, "content_type": 11, "object_id": "5", "object_repr": " 5. 47       .    propofol 2.0 \r\nmg/kg  rocuronium 1.0 mg/kg  ,    (TOF) 0  . \r\n      3    .   \r\n", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 34, "fields": {"action_time": "2024-07-04T05:45:06.807Z", "user": 1, "content_type": 11, "object_id": "6", "object_repr": " 6.             ?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 35, "fields": {"action_time": "2024-07-04T05:48:44.547Z", "user": 1, "content_type": 11, "object_id": "7", "object_repr": " 7.             ?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 36, "fields": {"action_time": "2024-07-04T05:49:46.457Z", "user": 1, "content_type": 11, "object_id": "8", "object_repr": " 8. 88       .    \r\n,   .      \r\n  ,  5   .  \r\n    ,      ", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 37, "fields": {"action_time": "2024-07-04T05:51:15.995Z", "user": 1, "content_type": 11, "object_id": "9", "object_repr": " 9.           position \r\n    ?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 38, "fields": {"action_time": "2024-07-04T05:51:55.367Z", "user": 1, "content_type": 11, "object_id": "10", "object_repr": " 10. 35          16 \r\nmm        . \r\n       (visual evoked potential, VEP)\r\n .   VEP     ", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 39, "fields": {"action_time": "2024-07-04T05:52:48.537Z", "user": 1, "content_type": 11, "object_id": "11", "object_repr": " 11. 46       (pituitary apoplexy)\r\n    .        \r\n?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 40, "fields": {"action_time": "2024-07-04T05:53:44.864Z", "user": 1, "content_type": 11, "object_id": "12", "object_repr": " 12.    57      \r\n(coil embolization)   .    \r\n    130/70 mmHg    .   \r\n   .      ", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 41, "fields": {"action_time": "2024-07-04T05:54:25.733Z", "user": 1, "content_type": 11, "object_id": "13", "object_repr": " 13. 55          (skull \r\nbase)      .   \r\n       (hyperchloremic metabolic \r\nacidosis)      ?", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 42, "fields": {"action_time": "2024-07-04T05:55:23.154Z", "user": 1, "content_type": 11, "object_id": "14", "object_repr": " 14. 49          \r\n .         \r\n 98% .  50%    pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 43, "fields": {"action_time": "2024-07-04T06:44:01.476Z", "user": 1, "content_type": 1, "object_id": "15", "object_repr": "Coag object (15)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 44, "fields": {"action_time": "2024-07-04T07:14:23.040Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 45, "fields": {"action_time": "2024-07-04T07:14:38.221Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 46, "fields": {"action_time": "2024-07-04T07:15:17.211Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 47, "fields": {"action_time": "2024-07-04T07:20:07.815Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Sp hold b p\", \"Sp restart a p\", \"Sp hold b c\", \"Sp restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 48, "fields": {"action_time": "2024-07-04T07:25:49.565Z", "user": 1, "content_type": 1, "object_id": "18", "object_repr": "Coag object (18)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 49, "fields": {"action_time": "2024-07-04T07:32:00.882Z", "user": 1, "content_type": 1, "object_id": "19", "object_repr": "Coag object (19)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 50, "fields": {"action_time": "2024-07-08T04:54:11.266Z", "user": 1, "content_type": 1, "object_id": "20", "object_repr": "Coag object (20)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 51, "fields": {"action_time": "2024-07-08T05:02:08.811Z", "user": 1, "content_type": 1, "object_id": "21", "object_repr": "Coag object (21)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 52, "fields": {"action_time": "2024-07-08T05:02:35.687Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 53, "fields": {"action_time": "2024-07-08T05:14:29.393Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Sp hold b p\", \"Sp restart a p\", \"Sp hold b c\", \"Sp restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 54, "fields": {"action_time": "2024-07-08T05:28:42.781Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 1, "change_message": "[{\"added\": {}}]"}}, {"model": "admin.logentry", "pk": 55, "fields": {"action_time": "2024-07-08T13:12:39.263Z", "user": 1, "content_type": 1, "object_id": "20", "object_repr": "Coag object (20)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 56, "fields": {"action_time": "2024-07-08T13:12:45.878Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 57, "fields": {"action_time": "2024-07-08T13:12:55.041Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 58, "fields": {"action_time": "2024-07-08T13:13:08.809Z", "user": 1, "content_type": 1, "object_id": "21", "object_repr": "Coag object (21)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx restart a p\", \"Nx restart a c\", \"Db restart a p\", \"Ap restart a p\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 59, "fields": {"action_time": "2024-07-08T13:14:38.387Z", "user": 1, "content_type": 1, "object_id": "1", "object_repr": "Coag object (1)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 60, "fields": {"action_time": "2024-07-08T13:14:57.448Z", "user": 1, "content_type": 1, "object_id": "2", "object_repr": "Coag object (2)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx restart a p\", \"Nx restart a c\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 61, "fields": {"action_time": "2024-07-08T13:15:13.684Z", "user": 1, "content_type": 1, "object_id": "3", "object_repr": "Coag object (3)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 62, "fields": {"action_time": "2024-07-08T13:15:22.607Z", "user": 1, "content_type": 1, "object_id": "4", "object_repr": "Coag object (4)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 63, "fields": {"action_time": "2024-07-08T13:16:27.430Z", "user": 1, "content_type": 1, "object_id": "5", "object_repr": "Coag object (5)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b c\", \"Nx restart a c\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 64, "fields": {"action_time": "2024-07-08T13:16:33.472Z", "user": 1, "content_type": 1, "object_id": "6", "object_repr": "Coag object (6)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 65, "fields": {"action_time": "2024-07-08T13:16:55.625Z", "user": 1, "content_type": 1, "object_id": "7", "object_repr": "Coag object (7)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 66, "fields": {"action_time": "2024-07-08T13:17:07.125Z", "user": 1, "content_type": 1, "object_id": "8", "object_repr": "Coag object (8)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b c\", \"Db hold b c\", \"Ap hold b c\"]}}]"}}, {"model": "admin.logentry", "pk": 67, "fields": {"action_time": "2024-07-08T13:17:12.734Z", "user": 1, "content_type": 1, "object_id": "8", "object_repr": "Coag object (8)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 68, "fields": {"action_time": "2024-07-08T13:17:21.958Z", "user": 1, "content_type": 1, "object_id": "9", "object_repr": "Coag object (9)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 69, "fields": {"action_time": "2024-07-08T13:17:34.828Z", "user": 1, "content_type": 1, "object_id": "10", "object_repr": "Coag object (10)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 70, "fields": {"action_time": "2024-07-08T13:17:39.764Z", "user": 1, "content_type": 1, "object_id": "11", "object_repr": "Coag object (11)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 71, "fields": {"action_time": "2024-07-08T13:18:00.396Z", "user": 1, "content_type": 1, "object_id": "13", "object_repr": "Coag object (13)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Nx hold b p\", \"Nx restart a p\", \"Nx hold b c\", \"Nx restart a c\", \"Db hold b p\", \"Db restart a p\", \"Db hold b c\", \"Db restart a c\", \"Ap hold b p\", \"Ap restart a p\", \"Ap hold b c\", \"Ap restart a c\"]}}]"}}, {"model": "admin.logentry", "pk": 72, "fields": {"action_time": "2024-07-08T13:18:10.799Z", "user": 1, "content_type": 1, "object_id": "14", "object_repr": "Coag object (14)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 73, "fields": {"action_time": "2024-07-08T13:18:15.329Z", "user": 1, "content_type": 1, "object_id": "14", "object_repr": "Coag object (14)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 74, "fields": {"action_time": "2024-07-08T13:18:26.000Z", "user": 1, "content_type": 1, "object_id": "15", "object_repr": "Coag object (15)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Db hold b c\", \"Ap hold b c\"]}}]"}}, {"model": "admin.logentry", "pk": 75, "fields": {"action_time": "2024-07-08T13:18:32.163Z", "user": 1, "content_type": 1, "object_id": "15", "object_repr": "Coag object (15)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 76, "fields": {"action_time": "2024-07-08T13:18:37.122Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 77, "fields": {"action_time": "2024-07-08T13:18:41.203Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 78, "fields": {"action_time": "2024-07-08T13:18:47.434Z", "user": 1, "content_type": 1, "object_id": "18", "object_repr": "Coag object (18)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 79, "fields": {"action_time": "2024-07-08T13:18:52.919Z", "user": 1, "content_type": 1, "object_id": "19", "object_repr": "Coag object (19)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 80, "fields": {"action_time": "2024-07-08T13:18:56.503Z", "user": 1, "content_type": 1, "object_id": "20", "object_repr": "Coag object (20)", "action_flag": 2, "change_message": "[]"}}, {"model": "admin.logentry", "pk": 81, "fields": {"action_time": "2024-07-10T13:01:04.185Z", "user": 1, "content_type": 1, "object_id": "11", "object_repr": "Coag object (11)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 82, "fields": {"action_time": "2024-07-10T13:01:20.617Z", "user": 1, "content_type": 1, "object_id": "12", "object_repr": "Coag object (12)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 83, "fields": {"action_time": "2024-07-10T13:01:58.306Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 84, "fields": {"action_time": "2024-07-10T13:02:19.352Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 85, "fields": {"action_time": "2024-07-10T13:02:39.058Z", "user": 1, "content_type": 1, "object_id": "18", "object_repr": "Coag object (18)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 86, "fields": {"action_time": "2024-07-10T13:03:00.577Z", "user": 1, "content_type": 1, "object_id": "21", "object_repr": "Coag object (21)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 87, "fields": {"action_time": "2024-07-10T13:03:23.751Z", "user": 1, "content_type": 1, "object_id": "22", "object_repr": "Coag object (22)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 88, "fields": {"action_time": "2024-07-10T13:03:47.527Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 89, "fields": {"action_time": "2024-07-10T13:04:44.981Z", "user": 1, "content_type": 11, "object_id": "14", "object_repr": " 14. 49          \r\n .         \r\n 98% .  50%    pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Image\"]}}]"}}, {"model": "admin.logentry", "pk": 90, "fields": {"action_time": "2024-07-10T13:05:31.771Z", "user": 1, "content_type": 11, "object_id": "14", "object_repr": " 14. 49          \r\n .         \r\n 98% .  50%    pH \r\n7.402, PaCO2 42 mmHg, PaO2 160 mmHg, BE -1.01 mmol/L", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"Image\"]}}]"}}, {"model": "admin.logentry", "pk": 91, "fields": {"action_time": "2024-07-10T13:09:41.771Z", "user": 1, "content_type": 1, "object_id": "16", "object_repr": "Coag object (16)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 92, "fields": {"action_time": "2024-07-10T13:09:51.534Z", "user": 1, "content_type": 1, "object_id": "17", "object_repr": "Coag object (17)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "admin.logentry", "pk": 93, "fields": {"action_time": "2024-07-10T13:10:09.815Z", "user": 1, "content_type": 1, "object_id": "23", "object_repr": "Coag object (23)", "action_flag": 2, "change_message": "[{\"changed\": {\"fields\": [\"DrugName\"]}}]"}}, {"model": "auth.permission", "pk": 1, "fields": {"name": "Can add coag", "content_type": 1, "codename": "add_coag"}}, {"model": "auth.permission", "pk": 2, "fields": {"name": "Can change coag", "content_type": 1, "codename": "change_coag"}}, {"model": "auth.permission", "pk": 3, "fields": {"name": "Can delete coag", "content_type": 1, "codename": "delete_coag"}}, {"model": "auth.permission", "pk": 4, "fields": {"name": "Can view coag", "content_type": 1, "codename": "view_coag"}}, {"model": "auth.permission", "pk": 5, "fields": {"name": "Can add neuraxial", "content_type": 2, "codename": "add_neuraxial"}}, {"model": "auth.permission", "pk": 6, "fields": {"name": "Can change neuraxial", "content_type": 2, "codename": "change_neuraxial"}}, {"model": "auth.permission", "pk": 7, "fields": {"name": "Can delete neuraxial", "content_type": 2, "codename": "delete_neuraxial"}}, {"model": "auth.permission", "pk": 8, "fields": {"name": "Can view neuraxial", "content_type": 2, "codename": "view_neuraxial"}}, {"model": "auth.permission", "pk": 9, "fields": {"name": "Can add log entry", "content_type": 3, "codename": "add_logentry"}}, {"model": "auth.permission", "pk": 10, "fields": {"name": "Can change log entry", "content_type": 3, "codename": "change_logentry"}}, {"model": "auth.permission", "pk": 11, "fields": {"name": "Can delete log entry", "content_type": 3, "codename": "delete_logentry"}}, {"model": "auth.permission", "pk": 12, "fields": {"name": "Can view log entry", "content_type": 3, "codename": "view_logentry"}}, {"model": "auth.permission", "pk": 13, "fields": {"name": "Can add permission", "content_type": 4, "codename": "add_permission"}}, {"model": "auth.permission", "pk": 14, "fields": {"name": "Can change permission", "content_type": 4, "codename": "change_permission"}}, {"model": "auth.permission", "pk": 15, "fields": {"name": "Can delete permission", "content_type": 4, "codename": "delete_permission"}}, {"model": "auth.permission", "pk": 16, "fields": {"name": "Can view permission", "content_type": 4, "codename": "view_permission"}}, {"model": "auth.permission", "pk": 17, "fields": {"name": "Can add group", "content_type": 5, "codename": "add_group"}}, {"model": "auth.permission", "pk": 18, "fields": {"name": "Can change group", "content_type": 5, "codename": "change_group"}}, {"model": "auth.permission", "pk": 19, "fields": {"name": "Can delete group", "content_type": 5, "codename": "delete_group"}}, {"model": "auth.permission", "pk": 20, "fields": {"name": "Can view group", "content_type": 5, "codename": "view_group"}}, {"model": "auth.permission", "pk": 21, "fields": {"name": "Can add user", "content_type": 6, "codename": "add_user"}}, {"model": "auth.permission", "pk": 22, "fields": {"name": "Can change user", "content_type": 6, "codename": "change_user"}}, {"model": "auth.permission", "pk": 23, "fields": {"name": "Can delete user", "content_type": 6, "codename": "delete_user"}}, {"model": "auth.permission", "pk": 24, "fields": {"name": "Can view user", "content_type": 6, "codename": "view_user"}}, {"model": "auth.permission", "pk": 25, "fields": {"name": "Can add content type", "content_type": 7, "codename": "add_contenttype"}}, {"model": "auth.permission", "pk": 26, "fields": {"name": "Can change content type", "content_type": 7, "codename": "change_contenttype"}}, {"model": "auth.permission", "pk": 27, "fields": {"name": "Can delete content type", "content_type": 7, "codename": "delete_contenttype"}}, {"model": "auth.permission", "pk": 28, "fields": {"name": "Can view content type", "content_type": 7, "codename": "view_contenttype"}}, {"model": "auth.permission", "pk": 29, "fields": {"name": "Can add session", "content_type": 8, "codename": "add_session"}}, {"model": "auth.permission", "pk": 30, "fields": {"name": "Can change session", "content_type": 8, "codename": "change_session"}}, {"model": "auth.permission", "pk": 31, "fields": {"name": "Can delete session", "content_type": 8, "codename": "delete_session"}}, {"model": "auth.permission", "pk": 32, "fields": {"name": "Can view session", "content_type": 8, "codename": "view_session"}}, {"model": "auth.permission", "pk": 33, "fields": {"name": "Can add board", "content_type": 9, "codename": "add_board"}}, {"model": "auth.permission", "pk": 34, "fields": {"name": "Can change board", "content_type": 9, "codename": "change_board"}}, {"model": "auth.permission", "pk": 35, "fields": {"name": "Can delete board", "content_type": 9, "codename": "delete_board"}}, {"model": "auth.permission", "pk": 36, "fields": {"name": "Can view board", "content_type": 9, "codename": "view_board"}}, {"model": "auth.permission", "pk": 37, "fields": {"name": "Can add exam", "content_type": 10, "codename": "add_exam"}}, {"model": "auth.permission", "pk": 38, "fields": {"name": "Can change exam", "content_type": 10, "codename": "change_exam"}}, {"model": "auth.permission", "pk": 39, "fields": {"name": "Can delete exam", "content_type": 10, "codename": "delete_exam"}}, {"model": "auth.permission", "pk": 40, "fields": {"name": "Can view exam", "content_type": 10, "codename": "view_exam"}}, {"model": "auth.permission", "pk": 41, "fields": {"name": "Can add question", "content_type": 11, "codename": "add_question"}}, {"model": "auth.permission", "pk": 42, "fields": {"name": "Can change question", "content_type": 11, "codename": "change_question"}}, {"model": "auth.permission", "pk": 43, "fields": {"name": "Can delete question", "content_type": 11, "codename": "delete_question"}}, {"model": "auth.permission", "pk": 44, "fields": {"name": "Can view question", "content_type": 11, "codename": "view_question"}}, {"model": "auth.user", "pk": 1, "fields": {"password": "pbkdf2_sha256$720000$FjTNNqtynRriPsdL6lg9ek$Nliuzp8mq0mp3PWNXiCYMPHk+yKLFJrpysGUwkMGM48=", "last_login": "2024-07-02T03:18:17.212Z", "is_superuser": true, "username": "admin", "first_name": "", "last_name": "", "email": "escapebaek@gmail.com", "is_staff": true, "is_active": true, "date_joined": "2024-06-24T06:28:42.868Z", "groups": [], "user_permissions": []}}, {"model": "auth.user", "pk": 3, "fields": {"password": "pbkdf2_sha256$720000$zema9bnqinWeCv0TlzFMrS$KAaEMbT3NuZcN0gB24zvMSpKg68dsBqJIpIU3Mp1ol8=", "last_login": "2024-06-26T09:15:45.813Z", "is_superuser": false, "username": "test", "first_name": "", "last_name": "", "email": "test@test.com", "is_staff": false, "is_active": true, "date_joined": "2024-06-26T05:52:16.728Z", "groups": [], "user_permissions": []}}, {"model": "contenttypes.contenttype", "pk": 1, "fields": {"app_label": "coag", "model": "coag"}}, {"model": "contenttypes.contenttype", "pk": 2, "fields": {"app_label": "coag", "model": "neuraxial"}}, {"model": "contenttypes.contenttype", "pk": 3, "fields": {"app_label": "admin", "model": "logentry"}}, {"model": "contenttypes.contenttype", "pk": 4, "fields": {"app_label": "auth", "model": "permission"}}, {"model": "contenttypes.contenttype", "pk": 5, "fields": {"app_label": "auth", "model": "group"}}, {"model": "contenttypes.contenttype", "pk": 6, "fields": {"app_label": "auth", "model": "user"}}, {"model": "contenttypes.contenttype", "pk": 7, "fields": {"app_label": "contenttypes", "model": "contenttype"}}, {"model": "contenttypes.contenttype", "pk": 8, "fields": {"app_label": "sessions", "model": "session"}}, {"model": "contenttypes.contenttype", "pk": 9, "fields": {"app_label": "board", "model": "board"}}, {"model": "contenttypes.contenttype", "pk": 10, "fields": {"app_label": "exam", "model": "exam"}}, {"model": "contenttypes.contenttype", "pk": 11, "fields": {"app_label": "exam", "model": "question"}}, {"model": "sessions.session", "pk": "8atvc4i7rsjl9etu1w9np804puh70fe6", "fields": {"session_data": ".eJxVjEEOwiAURO_C2hCgQMWle89AgPlI1UBS2pXx7rZJF7qceW_mzXxYl-LXTrOfwC5MstNvF0N6Ut0BHqHeG0-tLvMU-a7wg3Z-a6DX9XD_DkroZVvrcYA0MBjg4IazS9kISoCwVtgtxJgpalLJKgOQsGZ0WWpkoQAt2OcL-Vc4mA:1sOU25:j9VsZH8H2ZlOgkzNajYVh4aZdfMD8UBvnZCh6OxRzyY", "expire_date": "2024-07-16T03:18:17.215Z"}}, {"model": "sessions.session", "pk": "inyot7tkch7xjmdeurigy4uvqstgdsic", "fields": {"session_data": ".eJxVjEEOwiAURO_C2hCgQMWle89AgPlI1UBS2pXx7rZJF7qceW_mzXxYl-LXTrOfwC5MstNvF0N6Ut0BHqHeG0-tLvMU-a7wg3Z-a6DX9XD_DkroZVvrcYA0MBjg4IazS9kISoCwVtgtxJgpalLJKgOQsGZ0WWpkoQAt2OcL-Vc4mA:1sNliG:exB_GDb6UZJErp9Up97MGl3eD-tz2cW2vG5jCY9n2GE", "expire_date": "2024-07-14T03:58:52.977Z"}}]